GlassScriptPhysician profile
Robert Craig Martin
NPI 1275510489
$1,667.77
in general payments reported to CMS, 2019-2025
13 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $94.84 · 2021: $263 · 2022: $160 · 2023: $149 · 2024: $390 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $445.88 | 2020-2025 | Via Matrix, Novachor, Simplimax |
| Amarin Pharma, INC. | $303.59 | 2019-2020 | |
| Treace Medical Concepts, INC. | $155.84 | 2025 | |
| Smith+Nephew, INC. | $125.11 | 2019-2025 | Stravix Pl, Grafix Pl, Stravix |
| Stryker Corporation | $123.29 | 2019-2024 | Actishield, Allowrap, Citrefix |
| Biohaven Pharmaceuticals, INC. | $122.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $110.01 | 2021 | |
| Mylan Specialty L.P. | $108.44 | 2023 | Yupelri |
| Novo Nordisk INC | $98.20 | 2022 | |
| Paratek Pharmaceuticals, INC. | $35.44 | 2023-2025 | Nuzyra |
| Tactile Systems Technology INC | $21.22 | 2023 | Entre Plus, Flexitouch Plus |
| Osiris Therapeutics INC. | $18.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.